Dataset opportunity
Ensoma — 医疗影像数据集机会
由 Ensoma 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场在 2025 年的估值为 18 亿美元，预计将以 35.1% 的复合年增长率增长（2026-2033 年）。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press
<a href="https://www.fiercebiotech.com/biotech/ensoma-sheds-more-staff-pauses-preclinical-programs-home-lead-gene-therapy" hreflang="en">Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy</a>
fiercebiotech.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Ensoma 持有源自其正在进行的临床试验的专有医疗影像数据集，其中包含关于基因工程序列和 VLP 递送载体的极高敏感知识产权。这种影像、监管和病历数据的独特组合直接适用于开发和验证高精度诊断人工智能算法，提供对新型治疗反应的无与伦比的视角。
该数据集为进入医疗影像人工智能市场提供了战略切入点，该市场在2025 年的估值为18 亿美元，并预计将以激进的35.1% 的复合年增长率扩张。[8] 虽然访问受到 HIPAA/GDPR 的严格控制，并与活跃的 FDA/英国临床试验授权挂钩，但这种复杂性支撑了数据的稀有性和质量。对于认真的 AI 买家来说，这代表了一个可防御的资产，可以在快速增长的市场中建立显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床试验数据受严格的 HIPAA/GDPR 和道德法规约束；关于基因工程序列和 VLP 递送载体的极高敏感知识产权；数据与正在进行的 FDA/英国临床试验授权挂钩。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
证据证实 Ensoma 持有源自其一项新型基因疗法1/2 期临床试验的、高度专有的医疗影像数据集。这些数据极其稀有，并在英国监管部门的批准下合乎道德地获取，这是 AI 开发的关键因素。对于构建诊断人工智能的公司来说，该数据集提供了一个独特的机会，可以对无法从其他地方获取的高价值纵向患者数据进行算法训练。在预计每年增长超过 35% 的医疗影像 AI 市场中，这代表着创建下一代诊断工具的显著竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“病历”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求异常高，受市场推动，预计复合年增长率为 35.1%，因为人工智能集成对于诊断准确性和效率至关重要。[8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据胃口信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 目标明确 — Ensoma 是一家临床阶段的基因组药物公司，致力于开发疗法，而非销售数据；其产生的海量专有临床和基因组数据是其核心业务的副产品，使其成为理想目标。问题：该公司经历了重大的裁员，在 2025 年底裁员一半，并在 2026 年 8 月进一步裁员，以集中资源于其领先的临床项目；最初的来源原因“医疗影像数据集”不是其核心数据资产；其主要数据是与基因组、临床前和临床试验相关的数据。
- Deep Qualification40
⚠ 需要审查 — Ensoma 是一家临床阶段的生物技术公司，开发体内基因疗法，使其成为有价值的临床试验和基因组数据的持有者。然而，机会不匹配，因为没有证据表明存在所谓的“医疗影像数据集”，并且临床试验数据固有的监管限制使其作为独立资产的商业化非常复杂且不太可能。[许可受限；数据集类型与实际活动不符：机会假设侧重于“医疗影像数据集”，但 Ensoma 的实际业务是体内造血干细胞 (HSC) 工程。虽然其肿瘤学项目针对实体瘤，但其出版物或演示文稿中没有证据表明医学影像数据是他们生成或分析的核心数据模式。[1, 16, 17]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该证据表明数据集包含直接来自1/2 期临床试验的医学影像，提供了开发和验证诊断人工智能所需的稀有纵向患者数据。
Industrial data
这指向 Ensoma 独特的体内基因工程平台的专有数据，提供了深厚的技术背景，可以增强主要影像数据集在专业研发应用中的价值。
Regulatory records
这证实了数据集源自已获得英国临床试验授权的流程，向买家保证了其合乎道德的获取和符合严格的监管标准。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Ensoma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.8 billion in 2025, projected to grow at a 35.1% CAGR (2026-2033) (source: Grand View Research). [8]. Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Cropvue — 传感器遥测数据集机会
View opportunity →其他Lancium — 传感器遥测数据集机会
View opportunity →工业247Tailorsteel — 工业运营数据集机会
View opportunity →